Clinical safety of 1500 mg oral naltrexone overdose.

نویسنده

  • Albert Stuart Reece
چکیده

This case represents a clinical overdose of the largest known dose of oral naltrexone, equivalent to the taking of a whole bottle of the oral naltrexone preparation. The patient's intention was to control craving for alcohol and opiates. The patient quickly settled with expectant management. As such it demonstrates that earlier concerns that have been voiced in this area, particularly relating to naltrexone-related hepatotoxicity and depression, may have been overstated, at least in the experience of this patient. This patient's course was marked only by gastric irritation, of which she had some history. As such the present profile provides case report evidence consistent with more robust views of the patient safety of naltrexone itself, and opposing more cautious views. Her polydrug craving was suppressed for a period of 2 weeks, which raises the important question of the mechanism of action of naltrexone's generalised suppression of refractory hedonic consumptive addictive behaviours.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.

INTRODUCTION AND AIMS Naltrexone implants are used to treat opioid dependence, but their safety and efficacy remain poorly understood. We systematically reviewed the literature to assess the safety and efficacy of naltrexone implants for treating opioid dependence. DESIGN AND METHODS Studies were eligible if they compared naltrexone implants with another intervention or placebo. Examined outc...

متن کامل

Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.

AIMS To examine and compare mortality rates in patients treated with oral and implant naltrexone. DESIGN A retrospective cohort study. SETTING A community not-for-profit drug treatment clinic. PARTICIPANTS Patients treated with oral naltrexone (n = 2155, 17 207 patient-years) and implant naltrexone (n = 2389, 11 678 patient-years) for problematic opiate use between August 1997 and Decembe...

متن کامل

Naltrexone extended-release injection: an option for the management of opioid abuse

The United States Food and Drug Administration (FDA) approved naltrexone, a synthetic competitive antagonist at opioid receptors, in oral form in 1984 for use in the management of opioid abuse and addiction. Because naltrexone and its major metabolite, 6-β-naltrexone, are both competitive antagonists at opioid receptors - and thereby inhibit opioid agonist-induced effects including those desire...

متن کامل

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.

BACKGROUND There is an unmet need for safe and effective medicines to treat children with Crohn's disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells. AIMS The aims of this study were to evaluate the safety and tolerability of an opioid antagonist, naltrexone, in children with moderate to severe Crohn's disease. METHODS A pil...

متن کامل

Chapter 5 --Clinical Profile - SAMHSA/CSAT Treatment Improvement Protocols - NCBI Bookshelf

to ReVia ® (Research Institute of Addictions, 1995). It is not, however, a new medication. Its history extends back to 1915, when German scientist Uber J. Pohl documented antagonistic effects of N-allylnorcodeine on morphineinduced respiratory depression in laboratory animals. The clinical importance of Pohl's finding was not pursued until the 1940s with the synthesis of nalorphine, the first s...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • BMJ case reports

دوره 2010  شماره 

صفحات  -

تاریخ انتشار 2010